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Summary
Inflammatory bowel disease (IBD) is characterized by a
chronic relapsing intestinal inflammation, typically start-
ing in early adulthood. IBD is subdivided into two sub-
types, on the basis of clinical and histologic features:
Crohn disease and ulcerative colitis (UC). Previous ge-
nomewide searches identified regions harboring suscep-
tibility loci on chromosomes 1, 3, 4, 7, 12, and 16. To
expand our understanding of the genetic risk profile, we
performed a 9-cM genomewide search for susceptibility
loci in 268 families containing 353 affected sibling pairs.
Previous linkages on chromosomes 12 and 16 were rep-
licated, and the chromosome 4 linkage was extended in
this sample. New suggestive evidence for autosomal link-
ages was observed on chromosomes 1, 6, 10, and 22,
with LOD scores of 2.08, 2.07, 2.30, and 1.52, respec-
tively. A maximum LOD score of 1.76 was observed on
the X chromosome, for UC, which is consistent with the
clinical association of IBD with Ullrich-Turner syn-
drome. The linkage finding on chromosome 6p is of
interest, given the possible contribution of human leu-
kocyte antigen and tumor necrosis–factor genes in IBD.
This genomewide linkage scan, done with a large family
cohort, has confirmed three previous IBD linkages and
has provided evidence for five additional regions that
may harbor IBD predisposition genes.
Received October 13, 1998; accepted for publication January 11,
1999; electronically published February 19, 1999.
Address for correspondence and reprints: Dr. Mark E. Curran,
Associate Director of Genetics, Axys Pharmaceuticals, Inc., 11099
North Torrey Pines Road, La Jolla, CA 92037. E-mail: mark_curran
@axyspharm.com
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6403-0019$20.00
Introduction
Inflammatory bowel disease (IBD; MIM 601458,
266600, 191390) is a disorder of unknown etiology,
characterized by chronic relapsing inflammation of the
gastrointestinal tract. IBD is categorized into two main
subtypes, on the basis of clinical and histopathologic
features: Crohn disease (CD; MIM 266600) and ulcer-
ative colitis (UC; MIM 191390; Hamilton 1987; Po-
dolsky 1991). Clinical features include abdominal pain,
chronic diarrhea, rectal bleeding, weight loss, intestinal
stenoses, fistulae, and toxic megacolon. IBD is also as-
sociated with extraintestinal manifestations, such as ar-
thritis and uveitis (Nordgren et al. 1992). The disease
incidence peaks in early adulthood and is rising world-
wide, with a current prevalence of ∼1/1,000 in Western
countries (Probert et al. 1996; Shivananda et al. 1996).
Although the cause of IBD is unknown, a strong ge-
netic susceptibility for IBD is shown by both consistent
familial clustering of disease (Mayberry 1989; Orholm
et al. 1991; Colombel et al. 1996; Satsangi et al. 1996a)
and increased concordance in monozygotic twins (Tysk
et al. 1988; Thompson et al. 1996). Significant preva-
lence differences exist among different ethnic groups liv-
ing in the same geographic region, displayed by the two-
to eightfold higher prevalence in Ashkenazi Jews versus
non-Jews (Roth et al. 1989). Epidemiologic and clinical
features, such as the association with Ullrich-Turner syn-
drome (Price 1979; Arulanantham et al. 1980; Hayward
et al. 1996), cannot be explained on the basis of the
available genetic data. Estimates of sibling risk (ls) show
a range of 10–50, suggesting that genetic factors play a
significant role in predisposition to IBD (Fielding 1986;
Orholm et al. 1993; Peeters et al. 1996). A simple genetic
model of IBD inheritance has not been supported by
segregation analysis, suggesting a more complex pattern
of inheritance (Kuster et al. 1989; Orholm et al. 1993),
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Table 1
Overview of the Family Cohort
SIBSHIP
SIZE
CD UC
MIXED
CD/UC
TOTAL
ASPS
(ALL)Complete
Incomplete
Parents
Total
CD ASP Complete
Incomplete
Parents
Total
UC ASP Complete
Incomplete
Parents
Total
Mixed ASPs
2 55 (55) 59 (59) 114 (114) 36 (36) 42 (42) 78 (78) 17 (17) 21 (21) 38 (38) 230 (230)
3 5 (15) 9 (27) 14 (42) 4 (12) 8 (24) 12 (36) 2 (6) 7 (21) 9 (27) 35 (105)
4 1 (6) ) 1 (6) ) ) ) 1 (6) 1 (6) 2 (12) 3 ( 18)
Total 61 (76) 68 (86) 129 (162) 40 (48) 50 (66) 90 (114) 20 (29) 29 (48) 49 (77) 268 (353)
NOTE.—Affected sibling pairs (ASP) are ordered according to sibship size and disease type within the family. “Mixed” denotes sibships with
both UC and CD. Numbers in parentheses are the number of sibships and affected sib pairs. The availability of parents for the analysis of
allele sharing identical by descent is indcated for each subgroup in the column marked “incomplete parents.”
caused by multiple susceptibility genes and environmen-
tal factors (Koutroubakis et al. 1996).
Previous genomewide linkage analyses in 78 and 160
families of white northern European extraction (111 and
186 affected sibling pairs, respectively) defined candidate
regions on chromosomes 3, 7, 12, and 16 (Hugot et al.
1996; Satsangi et al. 1996b). The importance of the can-
didate regions on chromosomes 12 and 16 has been
confirmed by subsequent studies (Ohmen et al. 1996;
Curran et al. 1998; Duerr et al. 1998; Mirza et al. 1998).
A recent study using allele-sharing methods in 151 sib
pairs, as well as in 146 distant relative pairs, suggested
additional susceptibility loci on chromosomes 1p, 3q,
and 4q (Cho et al. 1998).
To further develop an understanding of the genetic
basis of IBD, we have assembled 353 affected sibling
pairs from 268 white northern European families
(United Kingdom, Germany, and the Netherlands). We
describe here the results of a genomewide search for IBD
susceptibility loci in this large collection of families.
Families and Methods
Family Ascertainment and Phenotypes
An international consortium identified and sampled
kindreds with 2 affected siblings given diagnoses of
IBD. Patients were recruited from IBD programs at
King’s College School of Medicine, Guy’s Hospital, and
St. Mark’s Hospital (London); Charite University Hos-
pital (Berlin); Academic Medical Center (Amsterdam);
and other central European medical centers and through
national patient organizations in Germany and the
United Kingdom. Written informed consent was ob-
tained from all study participants. Recruitment proto-
cols were approved by institutional review committees
at each participating center. The diagnosis of IBD and
the classification into CD or UC were determined by
standard diagnostic criteria, as described by Lennard-
Jones (1989) and Podolsky (1991). Ascertainment cri-
teria were determined prior to the initiation of patient
collection. For families originating from the United
Kingdom and the Netherlands, medical records for all
patients were reviewed by one or more of the principal
investigators. For families of German extraction, pos-
sible patients were directly examined by one or more of
the principal investigators. Alternatively, two written re-
cords, containing a detailed disease history and results
of all diagnostic procedures, were obtained for each pa-
tient and reviewed by the principal investigators. A ve-
nous blood sample was obtained from the affected sib-
lings and their parents, if possible. An overview of the
family cohort is given in table 1.
Genotyping
Genomic DNA was prepared from whole blood with
the Puregene system (Gentra Systems). A total of 358
highly polymorphic microsatellite markers, providing
genome coverage at an average density of 1/9.4 cM
(range 4–23.7 cM), were genotyped with fluorescent
methods, as described by Hall and Nanthakumar
(1997). In brief, individual DNA samples were arrayed
in 96-well microtiter plates and subjected to amplifica-
tion by PCR, with individual marker amplicons. The
amplified products were pooled, heat denatured, and
subjected to electrophoresis on denaturing polyacryl-
amide gels. We collected data using ABI 377 automated
DNA sequencers, and we performed data analyses using
GENESCAN (version 2.1) and GENOTYPER (version
1.1.1). Allele analyses and individual allele calling were
performed as described by Hall and Nanthakumar
(1997) and Idury and Cardon (1997). Genotype errors
as a result of non-Mendelian segregation in pedigrees
were detected and corrected as described by Hall and
Nanthakumar (1997).
To facilitate inclusion of markers from different ge-
netic maps (e.g., CEPH and the Cooperative Human
Linkage Center), marker order and distances were cal-
culated with genotype data from the 268 pedigrees.
Marker order did not change with respect to the CEPH
reference genetic maps. Compared with the CEPHmaps,
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Table 2
Power Estimates for Detecting Linkage at Zmax Thresholds
Zmax THRESHOLD
l  2 l  3
UC CD ALL UC CD ALL
1.5 .56 .71 .98 .90 .97 .99
2 .36 .55 .96 .76 .92 .99
3 .12 .29 .85 .44 .77 .99
NOTE.—Power estimates for detecting linkage at Zmax thresholds of
1.5, 2, and 3 for the sample investigated. Full information content and
a recombination fraction between 0.05 marker and disease locus were
assumed.
intermarker distances varied by 3 cM. On average,
there were 726 informative meioses for each marker,
although most meioses were phase-unknown, because
few grandparents were available for genotyping in this
family collection (the average number of phase-known
meioses per marker was 7). Genetic maps for each chro-
mosome were constructed with the automated mapping
program MULTIMAP (version 2.0; Matise et al. 1994).
The resulting distances between markers, determined by
the Kosambi map function, are given in centimorgans.
Statistical Analysis
Genetic analyses were conducted with the two stan-
dard diagnostic categories CD and UC, as described. A
third category, ALL, contains CD/CD, UC/UC, and CD/
UC (mixed) affected sib pairs (ASP). The ALL category
therefore represents IBD as a single phenotype for anal-
ysis. Allele frequencies for each marker were calculated
from the cohort genotype data with all individuals. Each
of the 358 markers in the genome scan was analyzed,
with two-point and multipoint nonparametric allele
sharing tests in affected sibling pairs, by use of MAP-
MAKER/SIBS with the “weighted pairs” option (Krug-
lyak et al. 1995). For multipoint analysis, LOD scores
were computed at 1-cM intervals along each chromo-
some. The mean information content across the entire
scan was 69%.
Power analyses were performed to determine the like-
lihood of detecting linkage under various gene effect
sizes, with sample sizes corresponding to the three phe-
notype categories in this study. The methods used to
determine the estimated power were the same as those
described by Risch (1990). These power calculations as-
sume fully informative matings. Because the average het-
erozygosity of our markers was ∼75%, and complete
parental information is not available for all families, the
actual power to detect linkage in this study will not reach
the values given in table 2. In addition, because markers
in this study were spaced at ∼10-cM intervals, the power
to detect linkage was calculated at a recombination frac-
tion of .05 between marker and disease locus (the av-
erage maximum distance between a potential disease lo-
cus to a marker locus). These power calculations are
shown in table 2.
Results
All families in this study were genotyped with a total
of 358 microsatellite markers, spanning the genome at
an average resolution of 9.4 cM. Nonparametric linkage
analysis of the entire sample (ALL) was performed, as
well as of the two distinct phenotypes of CD and UC.
Chromosomal regions with maximum LOD scores
(Zmax)1.5, in any of the three groups, are shown in
table 3, along with the two-point results from the re-
spective markers closest to the linkage peak. A Zmax of
1.5 corresponds to an approximate P value of .01 and
is considered a cutoff for suggestive evidence of linkage.
Linkages on chromosomes 12 and 16, described else-
where, have been confirmed in this sample, and the link-
age on chromosome 4 has been extended (table 3). Sug-
gestive evidence for linkage was observed on
chromosomes 1, 6, 10, and 22, with LOD scores of 2.08,
2.07, 2.30, and 1.52, respectively. The linkage evidence
on chromosome 1q corresponds in location to the ob-
servation reported by Cho et al. (1998) for the CD phe-
notype in their study. A Zmax of 1.71 was observed on
chromosome X for UC. The strongest evidence for link-
age across the genome is seen on chromosome 10, for
CD, on chromosome X, for UC, and on chromosome
1, for the combined phenotype of IBD (ALL). No sig-
nificant linkage results were observed when CD/UC or
mixed pairs were analyzed separately (data not shown).
Multipoint Zmax curves for CD, UC, and ALL IBD pairs,
for all chromosomes, are shown in figure 1.
The family collection has a 1.5-fold excess of CD over
the UC phenotype (table 1). These two phenotypes con-
tribute, to different degrees, to the linkage regions seen
in this study. The UC phenotype contributes most
strongly to the linkages on chromosomes 1, 4, and one
of the X-chromosome peaks. The CD phenotype dom-
inates the linkages on chromosomes 10, 12, and 16. A
more equal relationship is seen for the peaks on chro-
mosomes 6 and 22 (table 3 and fig. 1).
Discussion
To facilitate identification of IBD loci and enhance our
overall understanding of the genetic basis of IBD, we
sampled 268 families with IBD, yielding a total of 353
affected sibling pairs, and examined this population us-
ing two-point and multipoint linkage analyses. This co-
hort represents the largest IBD ASP collection reported
to date. In addition to providing substantial power to
detect IBD susceptibility loci, this sample includes 114
UC ASPs, providing an opportunity to identify UC-spe-
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Table 3
LOD Scores and Loci for IBD Linkage Regions
MULTIPOINT PEAK TWO-POINT FLANKING MARKERS
CHROMOSOME
PHENOTYPE
CATEGORY
Position
(cM)a Zmax
Average Sharing
at Peak P Valuesb MARKER CD Zmax UC Zmax ALL Zmax
1 ALL 242 2.08 .59 .0044 D1S2670 .36 .82 1.0
D1S2682 .79 1.22 1.43
4 UC 126 1.56 .59 .009 D4S1575 .00 .69 .06
D4S424 .00 1.15 .00
6 ALL 34 2.07 .57 .0028 D6S289 .49 .51 1.37
D6S276 .53 1.49 2.05
12 CD 67 1.82 .61 .0016 D12S303 2.15 .92 .98
D12S326 1.30 .10 .45
16 CD 25 1.71 .56 .0026 D16S409 1.12 .04 .74
D16S411 1.56 .10 1.49
10 CD 46 2.30 .60 .0014 D10S548 1.17 .00 .32
D10S197 .95 .12 .49
22 ALL 14 1.52 .56 .0038 D22S315 .18 .89 .88
D22S421 .45 .45 .88
X ALL 37 1.59 .68 (brother-brother) .007 DXS1202 1.27 .43 1.96
DXS1214 1.19 .03 .63
X UC 132 1.71 .83 (sister-sister) .005 DXS1001 .23 .83 .61
DXS1047 .11 .79 .00
NOTE.—Loci with multipoint Zmax11.5 in either the total IBD (ALL), CD, or UC samples were included. Two-point Zmax for the closest
markers to the multipoint peak are given for the total and sample subsets. The nominal P values shown are not corrected for multiple
testing.
a Marker distances were calculated from the families analyzed with the program MULTIMAP (Matise et al. 1994). Map distances are
given in Kosambi centimorgans from the p-telomeric marker of the chromosome (for chromosomes 1, 4, 6, 12, 16, 10, 22, and Xmarkers:
D1S468, D4S412, D6S344, D10S249, D12S99, D16S407, D22S420, and DXS1060, respectively).
b Probability values for autosomal Zmax were determined by Monte Carlo simulation of the genotypes in the families under analysis,
in which all allele frequencies, familial relationships, phenotypic data, and missing genotype patterns were preserved. Probability values
shown thus represent the proportion of times that Zmax values greater than or equal to the observed statistic were observed in the
simulations. The simulations were conducted 5,000 times for each Zmax. Complete genotype data for the markers on chromosome 12
were available for 162, 114, and 353 affected sibling pairs for UC, CD, and all families combined, respectively. The P values for the X
chromosome were calculated by converting the LOD scores to a x2statistic.
cific loci. Genomewide analyses of this population, with
average marker spacing of !10 cM, has enabled iden-
tification of several new IBD susceptibility regions and
provided important replication data supporting previ-
ously identified IBD loci. Evidence indicating IBD sus-
ceptibility loci was observed on chromosomes 1, 4, 6,
10, 12, 16, 22, and X (table 3).
New possible IBD predisposition regions on chro-
mosomes 1, 10, and 22 have been identified in the pre-
sent study. The susceptibility region on chromosome 10
is defined by the anonymous markers D10S547 and
D10S20 and is supported by a multipoint Zmax of 2.30
and peak average allele sharing of .60, when analyzed
for the CD phenotype. A second interesting region is
observed on chromosome 22 and is defined by markers
D22S420 and D22S280. This region is supported by a
multipoint Zmax of 1.52, defined by analysis of all IBD
ASPs in the cohort. Previous IBD genome scans provided
suggestive evidence for a locus on chromosome 1. In the
present study, a linkage maximum is observed on the
distal portion of chromosome 1q. This locus is located
∼100 cM and ∼160 cM from the regions previously
implicated by Hugot et al. (1996) and Cho et al. (1998),
respectively. These data suggest a new susceptibility lo-
cus for IBD on chromosome 1. There was nominal ev-
idence of linkage on 1q in the Cho et al. (1998) paper,
which might correspond to the data observed in this
study. The importance of these newly identified IBD loci
to the determination of the overall genetic risk for IBD
will need to be supported by replication studies in ad-
ditional populations.
Evidence of IBD linkage to the major histocompati-
bility complex (MHC) region of chromosome 6 was also
observed in this sample. This finding is particularly in-
teresting given that numerous associations with individ-
ual human leukocyte antigen (HLA) region genes, in-
cluding class I (Gleeson et al. 1972; van den Berg Loonen
et al. 1977; Purrmann et al. 1985; Biemond et al. 1986),
class II (Fujita et al. 1984; Toyoda et al. 1993; Nakajima
et al. 1995), and TNF-a alleles (Plevy et al. 1996; Bouma
et al. 1998), have been described. The association data
for HLA and TNF-a are not conclusive (Russell et al.
1975; Delpre et al. 1980; Smolen et al. 1982; Satsangi
et al. 1996c). Questions regarding the significance of an
Figure 1 Multipoint Zmax curves for all chromosomes are shown. Multipoint analyses were done with the MAPMAKER/SIBS program.
Results for CD (dashed line), UC (thin solid line), and all pairs (ALL, thick solid line) are shown. Genetic distances between markers were
estimated from the data set. The reported regions of linkage from previous scans are denoted with an asterisk (*), a plus sign () and a pound
sign (#), for the studies by Hugot et al. (1996), Satsangi et al. (1996b) and Cho et al. (1998), respectively.
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IBD risk factor on chromosome 6 stem in part from the
lack of linkage evidence implicating this region (Hugot
et al. 1994; Naom et al. 1996). Suggestive evidence for
linkage to the HLA region of chromosome 6 is now
provided by the present study. Recent association studies
have suggested a role for HLA in susceptibility to UC
(Bouma et al. 1997; Roussomoustakaki et al. 1997; Perri
et al. 1998; Uyar et al. 1998) and CD (Forcione et al.
1996). The association findings would be consistentwith
the contribution of UC and CD families to the chro-
mosome 6 linkage, in the present study. The present data
sets are insufficient to implicate HLA alleles as the only
genetic risk factor in the chromosome 6p linkage region.
As discussed below, there are a number of immunoreg-
ulatory genes in this region that may contribute to the
observed phenotypes. In summary, the observation of
evidence for linkage, coupled with the numerous asso-
ciation findings, suggests that a susceptibility gene for
IBD does exist in the HLA region of chromosome 6.
An increased incidence of IBD in patients with Ullrich-
Turner syndrome has been observed, suggesting a pos-
sible link between these disorders ( Price 1979; Arulan-
antham et al. 1980; Kohler and Grant 1981; Knudtzon
et al. 1988; Knudtzon and Svane 1988; Scarpa et al.
1996). This hypothesis is supported by evidence of X
chromosome linkages observed in this study. Interest-
ingly, the X-chromosome linkage curve has two peak
regions, with UC defining a linkage interval on distal
Xq (multipoint ), and ALL IBD providingZ  1.71max
evidence for linkage to distal Xp (multipoint Z max
). Elucidation of the role of the X chromosome in1.59
IBD, and possible implications for Ullrich-Turner syn-
drome, await further investigation.
IBD susceptibility regions located on chromosomes 3,
7, 12, and 16 have been identified in previous genome-
wide linkage scans (Hugot et al. 1996; Satsangi et al.
1996b). The loci on chromosomes 12 and 16 are sup-
ported by results from the present study. Additional IBD
susceptibility loci on chromosomes 1q, 3q, and 4q have
been reported (Cho et al. 1998). The investigators used
a methodology that exploits allele-sharing information
in ASPs ( ), as well as distant relative pairsN  151
( ). In addition to the methodologic differences,n  146
an ethnically more diverse population sample was an-
alyzed. In our population, we also observe evidence for
linkage to chromosome 4q, with the peak location ∼20
cM more distal when compared with the Marshfield ge-
netic map (Marshfield Center for Medical Genetics da-
tabase). The discrepancy, with regard to peak location,
is not unexpected for a complex disease (Kruglyak and
Lander 1996). It is therefore likely that both linkages
indicate the same chromosome 4 susceptibility locus.
The power to detect true susceptibility regions by
means of nonparametric linkage analyses is highly de-
pendent on the size of the population being tested and
the locus-specific effect. If we take into consderation a
LOD score threshold of 2 for a primary genome scan
analysis, our sample size exceeds the 80% power typi-
cally needed for genes with a small to moderate effect
( ), for the combined ALL IBD phenotype (tablel  2s
2). In this study, linkages defined by the UC and CD
phenotypes exhibit different degrees of statistical signif-
icance. This may indicate potential genetic differences
between the two phenotypes. Interpretation of these data
is complicated, however, by the following factors: (1)
since CD families constitute two-thirds of the analyzed
sample, there is a power bias in favor of CD; (2) the
clinical overlap between CD and UC may confound ef-
forts to genetically distinguish between the two phe-
notypes (Podolsky 1991); and (3) the stochastic nature
of the family sampling process can lead to variations in
LOD scores, without significant differences in the un-
derlying disease model (Suarez et al. 1994; Hampe et
al., in press). UC, although approximately twice as prev-
alent as CD in northern European populations (Shivan-
anda et al. 1996), has been studied in significant numbers
in only one genomewide analysis (Satsangi et al. 1996b),
which included 30 affected sibling pairs. In the present
study, with 114 UC affected sib pairs, we establish rep-
lication of UC linkage to chromosome 12 and provide
suggestive evidence for newUC regions on chromosomes
1, 4, and X. Although an important clinical issue, it is
likely that true differentiation between CD and UC will
not be possible until after the discovery of the variants
underlying genetic predisposition to IBD.
The pathophysiology of IBD is characterized by a dys-
regulated immune response of the intestinal mucosa. Al-
though the IBD susceptibility regions are large, it is use-
ful to note that many interesting candidate genes are
located in these regions. The chromosome 6 IBD interval
contains a series of important immune-response genes,
including the MHC, TNF-a, and TNF-b (Gleeson et al.
1972; van den Berg Loonen et al. 1977; Plevy et al.
1996); several complement factors that are thought to
be important inflammatory effectors (Carroll 1998); and
the NFKBIL1 gene (Baeuerle 1998). Integrins have key
roles in cellular adherence and are participants in in-
flammatory and immune responses. The integrin-b1
gene, located on chromosome 10, and the integrin-b7
and a5, genes on chromosome 12, are putative candi-
dates for IBD (Gahmberg et al. 1998). Cytokines and
their receptors are critical in proliferation and differ-
entiation of multiple cell types and are thought to be
involved in the pathogenesis of IBD (Schreiber et al.
1995; Rogler and Andus 1998). The interleukin-4 re-
ceptor and interleukin-2 genes are located within the
chromosome 16 and chromosome 4 linkage regions. Ev-
idence from a large association study indicates that the
interferon-g gene is not likely to be the IBD susceptibility
gene in the chromosome 12 linkage region (Hampe et
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al. 1999). Additional positional candidates for IBD in-
clude the TGF-b2 and TGF-b4 genes on chromosome
1q, which are involved in wound healing and tissue res-
toration (Rogler and Andus 1998; Schmid et al. 1998),
and the ubiquitin-conjugating enzyme E2G, which is
likely to be important in the processing of antigens
(Hochstrasser 1996). Direct investigations into a pos-
sible role of these genes in the cause of IBD are ongoing.
The autosomal linkages observed in this study overlap
with regions implicated in other autoimmune disorders:
the chromosome 12 linkage overlaps with regions im-
plicated in asthma and multiple sclerosis, and the chro-
mosome 16 linkage overlaps with a locus for
insulin-dependent diabetes mellitus, asthma, and exper-
imental autoimmune encephalitis (Becker et al. 1998).
These observationsmay indicate common etiologic path-
ways involved in the defective immunoregulation ob-
served in these disorders.
In conclusion, we have identified multiple potential
novel linkages for IBD and provided important repli-
cation data for several previously identified IBD link-
ages. These findings increase our overall understanding
of the genetic basis of IBD, may be useful for develop-
ment of genetic tests for differentiating among clinical
IBD phenotypes, and will ultimately facilitate identifi-
cation of the genes and molecular variants that cause
this disease.
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